WuXi Biologics (Cayman) Inc. (WXXWY)
WuXi Biologics (Cayman) Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Wuxi, JS, CN. The stock last traded at $10.20, down 8.68% on the session, giving a market capitalisation of $20.81B. On trailing twelve-month figures it carries a trailing P/E of 28.82, a net margin of 21.2%. Its beta of 0.60 implies it has historically moved less than the broad market.
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
WuXi Biologics (Cayman) Inc. is most often compared with the following Healthcare names: